<SEC-DOCUMENT>0001157523-15-001046.txt : 20150331
<SEC-HEADER>0001157523-15-001046.hdr.sgml : 20150331
<ACCEPTANCE-DATETIME>20150330175100
ACCESSION NUMBER:		0001157523-15-001046
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150330
FILED AS OF DATE:		20150331
DATE AS OF CHANGE:		20150330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		15735777

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51069487.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 16pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 16pt"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-family: Times New Roman; font-size: 16pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font>
    </p>
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-family: Times New Roman; font-size: 12pt">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-family: Times New Roman; font-size: 12pt"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Dated</b></font><font style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>March
      30, 2015</b></font><br><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b>
    </p>
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Form 20-F &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Yes &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman; font-size: 10pt">
      No &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-family: Times New Roman; font-size: 10pt">If &quot;Yes&quot; is
      marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): Not a</font>pplicable<br>
    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized. </font>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 6%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 44%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            March 30, 2015
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" style="padding-left: 0.0px; text-align: left" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" style="padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" style="padding-left: 0.0px; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-bottom: 2.0px; width: 6%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; padding-bottom: 2.0px; width: 44%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; padding-bottom: 2.0px; width: 3%; text-align: left" valign="top">
          By:
        </td>
        <td colspan="2" style="border-bottom: solid black 1.0pt; padding-left: 0.0px; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          Name:
        </td>
        <td style="padding-left: 0.0px; width: 42%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 6%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 44%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          Title:
        </td>
        <td style="padding-left: 0.0px; width: 42%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-family: Times New Roman; font-size: 10pt; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; padding-bottom: 2.0px; width: 7%; text-align: left" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <u><b>Exhibit</b></u>
          </p>
        </td>
        <td style="padding-left: 0.0px; padding-bottom: 2.0px; width: 5%; text-align: left" valign="bottom">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 88%; text-align: left" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td style="padding-left: 0.0px; width: 88%; text-align: left" valign="top">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap; width: 7%; text-align: left" valign="top">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td style="padding-left: 10.0px; width: 88%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            News Release &#8211; Aurinia Reports Fourth Quarter and Full Year 2014
            Financial Results and Highlights Initiation of its Open Label
            Clinical Study to Investigate the Impact of Voclosporin on Lupus
            Nephritis Biomarkers
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51069487ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Aurinia
      Reports Fourth Quarter and Full Year 2014 Financial Results and
      Highlights Initiation of Its Open Label Clinical Study to Investigate
      the Impact of Voclosporin on Lupus Nephritis Biomarkers</b></font>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--March 30, 2015--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;)
      has released its financial results for the fourth quarter and year ended
      December 31, 2014. Amounts, unless specified otherwise, are expressed in
      U.S. dollars.
    </p>
    <p style="text-align: left">
      In support of their on-going large randomized Phase 2b lupus nephritis
      clinical trial (&#8220;AURA-LV&#8221;), the Company announced on February 9, 2015
      the initiation of an open label, exploratory study called AURION to
      assess short term predictors of response using voclosporin in
      combination with mycophenolate mofetil (MMF) in patients with active
      lupus nephritis (LN). AURION will examine biomarkers of disease activity
      at 8 weeks and their ability to predict response at 24 and 48 weeks.
    </p>
    <p style="text-align: left">
      <b>Highlights in 2014</b>
    </p>
    <p style="text-align: left">
      On February 14, 2014, the Company completed a $52 million private
      placement (the &#8220;Offering&#8221;) pursuant to which the Company issued 18.9
      million Units (the &quot;Units&quot;). The Offering was led by venBio, New
      Enterprise Associates, Redmile Group, RA Capital Management, Great Point
      Partners, and Apple Tree Partners, with participation from various other
      institutional investors, including existing shareholders Lumira Capital,
      ILJIN Life Science Co. Ltd (ILJIN) and Difference Capital.
    </p>
    <p style="text-align: left">
      On June 26, 2014 the Company announced enrollment of the first patient
      in AURA-LV to evaluate the efficacy of voclosporin as a treatment for
      LN. LN is an inflammation of the kidneys, that if inadequately treated
      can lead to end-stage renal disease, making LN a serious and potentially
      life-threatening condition.
    </p>
    <p style="text-align: left">
      On September 2, 2014 the Company commenced trading on the NASDAQ Global
      Market under the trading symbol &#8220;AUPH&#8221;. The Company continues to trade
      on the Toronto Stock Exchange in Canada.
    </p>
    <p style="text-align: left">
      <b>Financial Results for 2014</b>
    </p>
    <p style="text-align: left">
      The Company had cash, cash equivalents and short term investments of
      $32.7 million at December 31, 2014. Aurinia believes its cash position
      will be sufficient to finance its operational needs until at least
      December 31, 2016. However, future cash requirements could vary
      materially from current estimates due to a number of factors including
      the costs associated with its clinical trial and potential strategic
      opportunities.
    </p>
    <p style="text-align: left">
      The Company&#8217;s activities were focused on patient recruitment, enrollment
      and treatment activities for AURA-LV.
    </p>
    <p style="text-align: left">
      For the year ended December 31, 2014, the Company recorded a net
      consolidated loss of $16.7 million or $0.57 per common share, as
      compared to a consolidated net loss of $2.7 million or $0.42 per common
      share in 2013. The higher consolidated net loss reflected a significant
      increase in operational activities in 2014 as the Company was able to
      move forward with its strategic plan upon completion of the February 14,
      2014 financing.
    </p>
    <p style="text-align: left">
      The Company incurred net research and development expenditures of $9.1
      million for the year ended December 31, 2014, as compared to $2.0
      million for the same period in 2014. Research and development
      expenditures in 2014 reflected Phase 2b LN trial costs including patient
      recruitment, enrollment and treatment activity expenditures. The Phase
      2b LN study was at the planning stage in the fourth quarter of 2013 and
      therefore costs were much less in 2013.
    </p>
    <p style="text-align: left">
      The Company incurred corporate, administration and business development
      expenditures of $6.9 million for the year ended December 31, 2014, as
      compared with $2.3 million for the same period in fiscal 2013.
    </p>
    <p style="text-align: left">
      Corporate, administration and business development expenditures for 2014
      were higher than the comparable period in 2013 as a result of increased
      business activity levels as the Company implemented its strategic plan
      and supported the Phase 2b LN trial activities. Corporate,
      administration and business development expense in 2014 also included
      $1.9 million of non-cash stock option compensation expense related to
      the issuance of stock options in 2014 to certain officers and directors
      of the Company whereas stock option compensation expense in 2013 was
      $135,000 as no stock options were granted throughout 2013.
    </p>
    <p style="text-align: left">
      Other expense (income) reflected income of $1.7 million for the year
      ended December 31, 2014 compared to other expense of $906,000 for 2013.
      The Company recorded non-cash gains of $2.8 million on extinguishment
      and re-measurement of warrant liability initially recorded upon the
      completion of the private placement on February 14, 2014. The Company
      also recorded as other expense, a revaluation adjustment on contingent
      consideration to ILJIN in the amount of $848,000 in 2014. Other expense
      in 2013 reflected fair value adjustments arising from the Plan of
      Arrangement completed on September 20, 2013 whereby the Company realized
      a gain on Aurinia Pharma Corp. of $3.5 million and a loss on contract
      settlement with ILJIN of $4.3 million.
    </p>
    <p style="text-align: left">
      <b>Financial results for the fourth quarter ended December 31, 2014</b>
    </p>
    <p style="text-align: left">
      The Company reported a consolidated net loss of $4.9 million or $0.15
      per common share for the three months ended December 31, 2014, as
      compared to an adjusted consolidated net loss of $1.7 million or $0.14
      per common share for the three months ended December 31, 2013.
    </p>
    <p style="text-align: left">
      Research and development expenditures increased to $3.1 million in the
      fourth quarter of 2014, compared to $691,000 in the fourth quarter of
      2013.
    </p>
    <p style="text-align: left">
      Corporate and administration expenses were $1.4 million for the fourth
      quarter of 2014, compared to $899,000 for the fourth quarter of 2013.
    </p>
    <p style="text-align: left">
      The audited financial statements and the Management's Discussion and
      Analysis for the year ended December 31, 2014, are accessible on
      Aurinia's website at <u>www.auriniapharma.com</u> or on SEDAR at <u>www.sedar.com</u>
      or on EDGAR at <u>www.sec.gov/edgar</u>.
    </p>
    <p style="text-align: left">
      <i><b>About Aurinia</b></i>
    </p>
    <p style="text-align: left">
      Aurinia is a clinical stage pharmaceutical company focused on the global
      nephrology market. It is currently enrolling patients in its Phase 2b
      clinical trial to evaluate the efficacy of its drug, voclosporin, as a
      treatment for LN. LN is an inflammation of the kidneys, that if
      inadequately treated can lead to end-stage renal disease, making LN a
      serious and potentially life-threatening condition.
    </p>
    <p style="text-align: left">
      Voclosporin is a novel and potentially best in class calcineurin
      inhibitor (&#8220;CNI&#8221;) with extensive clinical data in over 2,600 patients in
      other indications. Voclosporin is made by a modification of a single
      amino acid of the cyclosporine molecule (a CNI approved for use in
      transplant patients since 1983). This modification results in a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency vs. cyclosporine, an altered metabolic profile, and
      potential for flat dosing.
    </p>
    <p style="text-align: left">
      We seek Safe Harbor.
    </p>
    <p style="text-align: left">

    </p>
    <p>
      CONTACT:<br>
    </p>
    <p style="text-align: left">
      Aurinia Pharmaceuticals Inc.<br>Mr. Michael Martin, 250-708-4272<br>Chief
      Operating Officer<br>250-744-2498 (fax)<br>mmartin@auriniapharma.com<br>or<br>Mr.
      Dennis Bourgeault, 780-643-2260<br>Chief Financial Officer<br>780-484-4105
      (fax)<br><u>dbourgeault@auriniapharma.com</u>
    </p>
    <p style="text-align: left">

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
